Lilly snaps up Engage to advance non-viral genetic medicines

Lilly snaps up Engage to advance non-viral genetic medicines is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Delilah Alvarado · 2026-05-20

The acquisition is Lilly’s latest push into genetic medicine, giving it a non-viral gene editing platform.

Source: BioPharma Dive